March 21, 2017 / 9:16 PM / 4 months ago

BRIEF-Ardelyx expects to announce T3MPO-2's results during 2H 2017

1 Min Read

March 21 (Reuters) - Ardelyx Inc

* Ardelyx - achieved full enrollment of over 600 patients for one of its pivotal phase 3 clinical trials in u.s. Evaluating tenapanor in ibs-c patients

* Ardelyx inc - expects to announce t3mpo-2's results during second half of 2017 - sec filing

* Ardelyx inc - company expects to have data from onset-of-action clinical trial of rdx7675 for hyperkalemia in q3 of 2017

* Ardelyx - achieved full enrollment of over 300 patients for its open-label, long-term safety study in which patients receive tenapanor for up to 1 year

* Ardelyx - to announce results from one of its pivotal phase 3 clinical trials in u.s. Evaluating tenapanor in ibs-c patients (t3mpo-1) during q2 of 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below